Trials / Completed
CompletedNCT04915989
Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals
A Phase 1, Multicenter, Open-Label, Single Arm Study to Investigate the Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Genexine, Inc. · Industry
- Sex
- All
- Age
- 55 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
The objective of the study is to demonstrate safety and immunogenicity of COVID-19 preventive DNA vaccine in elderly individuals.
Detailed description
This clinical study is a phase 1 clinical trial to investigate the safety and immunogenicity of COVID-19 preventive vaccine by intramuscularly administration in the elderly. This study is designed as single arm, open-labeled and a total of 30 subjects will be enrolled.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GX-19N | DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen |
Timeline
- Start date
- 2021-02-16
- Primary completion
- 2022-04-01
- Completion
- 2022-04-01
- First posted
- 2021-06-07
- Last updated
- 2024-03-01
Locations
2 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04915989. Inclusion in this directory is not an endorsement.